OmniAb, Inc. filings document the public-company disclosures of an antibody discovery technology business that licenses its platform to pharmaceutical, biotechnology and academic partners. Its Form 8-K reports furnish operating and financial results, partner program updates, guidance-related disclosures and other material events tied to the company’s licensing, service, milestone and royalty model.
The company’s proxy and governance filings cover annual meeting matters, director elections, auditor ratification, shareholder voting results and bylaw amendments addressing proxy-solicitation procedures and stockholder proposal mechanics. OmniAb filings also identify its emerging growth company status, Nasdaq-listed common stock and warrants, and recurring capital-structure and governance disclosure topics.
OmniAb, Inc. reported sharply improved first-quarter 2026 results while remaining unprofitable. Revenue rose to $14.4 million from $4.2 million, driven mainly by a $10.0 million increase in license and milestone revenue. Service, xPloration and royalty revenue also grew modestly.
Operating expenses were broadly flat at $22.3 million, as lower research and development and general and administrative costs offset higher amortization of intangibles, including a $2.9 million impairment of certain legacy ion channel customer relationship assets. Net loss narrowed to $7.7 million from $18.2 million, or $0.06 per share versus $0.17 per share.
OmniAb ended March 31 2026 with $49.1 million in cash, cash equivalents and short-term investments and believes this balance can fund operations for at least the next 12 months. The company continues to scale its antibody discovery platform, with 107 active partners, 409 active programs and 3 approved partnered products.
OmniAb reported a much stronger first quarter of 2026, with revenue rising to $14.4 million from $4.2 million a year earlier, mainly on higher milestone revenue. Total GAAP costs and operating expenses were $22.3 million, roughly flat year over year, while non‑GAAP cash costs and operating expenses fell to $12.3 million from $14.7 million.
Net loss narrowed to $7.7 million, or $0.06 per share, compared with $18.2 million, or $0.17 per share, in the prior‑year quarter. OmniAb raised 2026 revenue guidance to $28–$33 million and now expects year‑end cash and cash equivalents of $33–$38 million, reflecting confidence in partner progress and its technology platform.
OmniAb, Inc. will hold its 2026 Annual Meeting of Shareholders on June 17, 2026 at 8:00 a.m. Pacific Time in Emeryville, California. Shareholders of record as of April 23, 2026 will vote on electing two Class I directors and ratifying Ernst & Young LLP as auditor for 2026.
The proxy highlights a seven-member board with an independent chair, fully independent key committees, and restrictions on insider trading, pledging and hedging. It details executive pay, with CEO Matthew Foehr’s 2025 package combining salary, cash bonus and stock-based incentives tied to strategic, technology, portfolio, financial, and culture goals.
OmniAb, Inc. director Philip J. Gotwals reported an exercise of restricted stock units into common shares. On April 21, 2026, 13,333 Restricted Stock Units converted into 13,333 shares of Common Stock at a stated price of $0.0000 per share.
Following the transaction, he directly holds 13,333 shares of Common Stock and 46,667 Restricted Stock Units. The RSUs vest in three substantially equal annual installments beginning April 21, 2026, subject to his continued service with OmniAb through each vesting date.
OmniAb, Inc. director Steven C. Crouse acquired 13,333 shares of Common Stock through the exercise of Restricted Stock Units at a stated price of $0.00 per share. Following the transaction, he directly holds 13,333 Common shares and 46,667 Restricted Stock Units.
The 13,333 Restricted Stock Units referenced in the filing vest in three substantially equal annual installments beginning on April 21, 2026, subject to Crouse’s continued service. Each Restricted Stock Unit represents a contingent right to receive one share of OmniAb’s Common Stock.
The issuer reported a Form 144 notice for the proposed sale of 13,542 shares of Common Stock classified as Restricted Stock and labeled Compensation. The filing lists two prior sales in February: 6,828 and 9,301 shares.
OmniAb, Inc. President and CEO Matthew W. Foehr reported routine equity compensation activity. On April 7, 2026, 36,459 Restricted Stock Units vested and were converted into the same number of OmniAb common shares at no exercise price. To satisfy tax withholding obligations tied to this vesting, 19,244 shares of common stock were sold in mandated “sell-to-cover” transactions at a weighted average price of $1.49 per share, rather than at Foehr’s discretion. Following these transactions, Foehr directly holds 4,420,492 shares of OmniAb common stock and 309,376 RSUs, indicating that the sale represents a small portion of his overall equity position.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for proposed sale of 36,459 shares of restricted common stock on 04/07/2026, listed as compensation securities. The filing also records prior sales of 20,754 shares on 02/17/2026 and 30,843 shares on 02/18/2026.
OmniAb, Inc. Executive VP, Finance and CFO Kurt A. Gustafson reported routine equity compensation activity. On April 7, 2026, 13,542 Restricted Stock Units vested, converting into the same number of common shares at no cost. To cover tax withholding on this vesting, 6,913 common shares were sold in a mandated sell-to-cover transaction at a weighted average price of $1.49 per share, rather than as a discretionary sale. After these events, he directly holds 261,483 shares of OmniAb common stock, reflecting prior transfers including 13,997 shares delivered to an ex-spouse under a domestic relations order.